SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-002770
Filing Date
2021-03-11
Accepted
2021-03-11 08:35:37
Documents
14
Period of Report
2021-03-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K blph-20210311x8k.htm   iXBRL 8-K 45768
2 EX-99.1 blph-20210311xex99d1.htm EX-99.1 121081
3 GRAPHIC blph-20210311xex99d1001.jpg GRAPHIC 4509
  Complete submission text file 0001558370-21-002770.txt   302212

Data Files

Seq Description Document Type Size
4 EX-101.SCH blph-20210311.xsd EX-101.SCH 3043
5 EX-101.LAB blph-20210311_lab.xml EX-101.LAB 15410
6 EX-101.PRE blph-20210311_pre.xml EX-101.PRE 9812
7 EXTRACTED XBRL INSTANCE DOCUMENT blph-20210311x8k_htm.xml XML 4694
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

IRS No.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 21731939
SIC: 2834 Pharmaceutical Preparations